Welcome to the 3rd Precision Medicine in Inflammatory Bowel Disease Summit
Deliver Safe & Effective Precision Therapies to Every IBD Patient
The Inflammatory Bowel Disease (IBD) field is abuzz with groundbreaking data, high-impact deals, and strategic partnerships. Sanofi and Teva’s IBD candidate is generating excitement with its ongoing success, Roche’s RVT-3101 is making waves in Phase 3 trials, and Merck & Co.’s MK-7240 continues to fuel optimism. With momentum building, the stage is set for a transformative shift in IBD treatment.
Catalysing this innovation, the 3rd Precision Medicine in Inflammatory Bowel Disease Summit returns to Boston in May, uniting 80+ biopharma, diagnostics providers, and academic leaders to explore breakthrough advancements in AI, biomarker development, patient stratification, and novel therapies.
Join us for 3 days of expert-led discussions, including a Technology Innovations in IBD Focus Day and exclusive networking opportunities, as this meeting offers unmatched opportunities to connect with decision makers, discover transformative solutions, and shape the future of precision medicine in IBD. Don’t miss your chance to lead progress in this rapidly evolving field!
World-Class Speaker Faculty Snapshot:
Mark Osterman
Vice President, Early Differentiation and Pipeline for Immunology, Cardiovascular, and Neuroscience
Bristol Myers Squibb
Sarah Grant
Vice President & Head of Early Clinical Development Respiratory & Immunology
AstraZeneca
Stefan Schreiber
Professor of Medicine, Director Department of Internal Medicine, University Hospital Schleswig-Holstein (UKSH)
Kiel University
Who’s Attending in May?
BRAND-NEW 2025 BROCHURE
Hear What Previous Attendees Had to Say:
“Intimate and the content was all very relevant. The networking sessions were great to get to know the other participants”
Senior Vice President, Drug Discovery, C4X Discovery
“I loved that it was a relatively small meeting but only with experts in the same field. This enabled me to have many interactions and start new collaborations. Because the topic was very focused, most of the talks were of high interest to me”
Associate Professor, Medicine, Beth Israel Deaconess Medical CentreIT
“Good talks, science, and an opportunity to learn about specifics of drug development in IBD”
Director, Research Alliances, INOTREM
Other Events in the Series
